

1642

ABX-PF/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group : 1642  
Applicants : Bruce D. Cohen et al.  
Application No.: 10/038,591 Confirmation No.: 1445  
Filed : January 4, 2002  
For : Antibodies to Insulin-like Growth Factor Receptor

RECEIVED  
FEB 10 2003  
TECH CENTER 1600/2800

New York, New York  
February 4, 2003

Hon. Commissioner for Patents  
P.O. Box 2327  
Arlington, Virginia 22202

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but before the mailing date of the first Office Action on the merits;
- ☐ before the mailing of a first Office action after the filing of a request for continued examination;
- ☐ after the mailing date of a first Office Action on the merits but before the mailing date of a Final Action or a Notice of Allowance.

In accordance with 37 C.F.R. § 1.97(b)(3), no fee is due in connection with this Information Disclosure Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

Karen E. Brown

James F. Haley, Jr. (Reg. No. 27,794)

Jane T. Gunnison (Reg. No. 38,479)

Attorneys for Applicants

Karen E. Brown (Reg. No. 43,866)

Agent for Applicants

FISH & NEAVE

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

I Heroby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
COMMISSIONER FOR  
PATENTS P.O. BOX 2327  
ARLINGTON, VA 22202 on February 4, 2003

Charles J. Smith  
Signature of Person Signing



ABX-PF/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1642  
Applicants : Bruce D. Cohen et al.  
Application No. : 10/038,591  
Confirmation No. : 1445  
Filed : January 4, 2002  
For : Antibodies to Insulin-like Growth  
Factor I Receptor

RECEIVED  
FEB 10 2003  
TECH CENTER 1600/2900

New York, New York  
February 4, 2003

Hon. Commissioner for Patents  
P.O. Box 2327  
Arlington, Virginia 22202

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants  
hereby make of record the references listed below. Copies of  
these references are enclosed.<sup>1</sup>

---

<sup>1</sup> For the Examiner's convenience, applicants have also enclosed  
a completed Form PTO-1449, listing these documents.



UNITED STATES PATENT DOCUMENT

<u>Inventor</u>	<u>Patent No.</u>	<u>Issue Date</u>
Baserga et al.	6,084,085	July 4, 2000

FOREIGN PATENT DOCUMENTS

<u>Publication No.</u>	<u>Publication Date</u>
WO 00/50067	August 31, 2000

OTHER REFERENCES

DiGiovanni, John, et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," *Proc. Natl. Acad. Sci. USA*, 97:3455-3460 (2000).

Drexhage, H.A. & Wulffraat, N.M., "Endocrine autoimmune diseases," *Netherlands Journal of Medicine*, 45:285-293 (1994).

Kim, Bhumsoo, et al., "Insulin receptor substrate 2 and shc play different roles in insulin-like growth factor I signaling," *Journal of Biological Chemistry*, 273:34543-34550 (1998).

Smith, Lois E., et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor," *Nature Medicine*, 5:1390-1395 (1999).

Tappy, Luc, et al., "Antibodies to insulin-like growth factor I receptors in diabetes and other disorders," *Diabetes*, 37:1708-1714 (1988).

Thompson, Kathleen, et al., "Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature," *Pediatric Research*, 32:455-459 (1992).

RECEIVED  
FEB 10 2003  
TECH CENTER 1600/2900

Weightman, David R., et al., "Autoantibodies to IGF-1 binding sites in thyroid associated opthalmopathy," *Autoimmunity*, 16:251-257 (1993).

Wraight, Christopher, et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides," *Nature Biotechnology*, 18:521-526 (2000).

#### REMARKS

It is respectfully requested that the Examiner (1) fully consider the enclosed references during the examination of this application; (2) initial the enclosed copy of Form PTO-1449 in the appropriate places to indicate that the references have been considered; and return a copy of the initialed Form to the undersigned in accordance with MPEP § 609 and § 2001.06(b).

Respectfully submitted,

Karen E. Brown

James F. Haley, Jr. (Reg. No. 27,794)  
Jane T. Gunnison (Reg. No. 38,479)  
Attorney for Applicants  
Karen E. Brown (Reg. No. 43,866)  
Agent for Applicants

FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax: (212) 596-9090

I hereby certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
COMMISSIONER FOR


DESBERTS P.O. BOX 2327  
ARLINGTON, VA 22202

on February 4, 2003

Cheryl J. Saint-John  
Goodman

Signature of Person Signing

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ABX-PF/2APPLN. NO.  
10/038,591APPLICANT  
Bruce D. Cohen, et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,084,085	July 4, 2000	Baserga et al.	536	23.5	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/50067	August 31, 2000	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	DiGiovanni, John, et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," <u>Proc. Natl. Acad. Sci. USA</u> , 97:3455-3460 (2000).
	Drexhage, H.A. & Wulffraat, N.M., "Endocrine autoimmune diseases," <u>Netherlands Journal of Medicine</u> , 45:285-293 (1994).
	Kim, Bhumsoo, et al., "Insulin receptor substrate 2 and shc play different roles in insulin-like growth factor I signaling," <u>Journal of Biological Chemistry</u> , 273:34543-34550 (1998).
	Smith, Lois E., et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor," <u>Nature Medicine</u> , 5:1390-1395 (1999).
	Tappy, Luc, et al., "Antibodies to insulin-like growth factor I receptors in diabetes and other disorders," <u>Diabetes</u> , 37:1708-1714 (1988).
	Thompson, Kathleen, et al., "Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature," <u>Pediatric Research</u> , 32:455-459 (1992).
	Weightman, David R., et al., "Autoantibodies to IGF-1 binding sites in thyroid associated opthalmopathy," <u>Autoimmunity</u> , 16:251-257 (1993).
	Wraight, Christopher, et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides," <u>Nature Biotechnology</u> , 18 :521-526 (2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FEB 10 2003

TECH CENTER 1600 1900